12th week of 2012 patent applcation highlights part 37 |
Patent application number | Title | Published |
20120070412 | HCV Inhibitor and Therapeutic Agent Combinations - The present invention is directed to a combination product for treating or ameliorating hepatitis C virus (HCV) infection or disorders or symptoms associated therewith in a subject in need thereof comprising, a HCV inhibitor and one or more therapeutic agents selected from either or both a HCV protease inhibitor and one or more different therapeutic agents administered in combination in an effective amount to the subject. | 2012-03-22 |
20120070413 | METHOD OF TREATING CANCER WITH SUBSTITUTED AMIDE DERIVATIVES - Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 2012-03-22 |
20120070414 | Controlling disease vectors from insects and arthropods using preconidial mycelium and extracts of preconidial mycelium from entomopathogenic fungi - The present invention utilizes extracts of the pre-sporulation (preconidial) mycelial stage of entomopathogenic fungi as insect and arthropod attractants and/or pathogens and can be employed to limit the zoonotic and plant diseases they transmit. The fungus can be cultivated on grain, wood, agricultural wastes or other cellulosic material and extracts can be made thereof. More than one fungus and substrate can be used in combination with one or more antimicrobial, antiprotozoal, antiviral, or genetically modified agents that result in reduced spread of contagions and lessens the damage they inflict on animals and plants. | 2012-03-22 |
20120070415 | AZIDO NUCLEOSIDES AND NUCLEOTIDE ANALOGS - Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a disease and/or a condition, including an infection from a paramyxovirus and/or an orthomyxovirus, with a nucleoside, a nucleotide and an analog thereof. Examples of viral infections include a respiratory syncytial viral (RSV) and influenza infection. | 2012-03-22 |
20120070416 | Macrocyclic Proline Derived HCV Serine Protease Inhibitors - The present invention discloses compounds of Formula I or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2012-03-22 |
20120070417 | ANTI-INFLUENZA FORMULATIONS AND METHODS - The invention relates to pharmaceutical compositions that contain a calcium salt as an active ingredient and also comprise another anti-influenza agent, and to methods for treating or preventing influenza virus infection. | 2012-03-22 |
20120070418 | STEM CELLS FOR MUSCULOSKELETAL TISSUE REPAIR - The stem cells that can be propagated and maintained for extended periods of time in culture in the absence of a feeder layer, and can be used to repair tissue damage. These cells are derived from fetal tissues and are able to repair different types of damage in musculoskeletal system, with significantly greater efficacy than stem cells derived from adult tissues. These cells are hypoimmunogenic and can be used for allogeneic transplantation to vertebrate hosts having disease and/or damage in musculoskeletal and other tissues. The cells can be administered by direct injection to the site in need of repair or by systemic (e.g., intravenous) administration. The stem cells of the invention are capable of migrating to the sites in need of repair, and of adopting a phenotype most appropriate to the nature of the damage, injury or disease. | 2012-03-22 |
20120070419 | METHOD OF ALTERING THE DIFFERENTIATIVE STATE OF A CELL AND COMPOSITIONS THEREOF - The present invention provides a method of altering the differentiative state of cells utilizing innovative protein expression constructs encoding transcription factors. The methods and compositions described herein may be used to generate induced pluripotent stem (iPS) cells, as well as differentiate, transdifferentiate or dedifferentiate cells of various epigenetic status. The method includes introduction of a nucleic acid construct, or expression product thereof, into a cell, and culture of the cell under culture conditions that efficiently converts the cell into a pluripotent cell, enhances the retention of the pluripotent state or efficiently converts the cell into a cell of a cell lineage corresponding to endoderm, mesoderm or ectoderm. | 2012-03-22 |
20120070420 | COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC AND NEURODEGENERATIVE DISORDERS - Treatment methods are disclosed for psychiatric and neurodegenerative disorders by treatment of the patient with platelet-rich plasma (PRP). PRP is administered to areas of the brain that have been identified as associated with the psychiatric or neurodegenerative disorder to replenish the dysfunctional tissue. | 2012-03-22 |
20120070421 | Synergistic Fungicidal Mixtures - The present invention relates to fungicidal mixtures, comprising a compound of formula I and one fungicidal component II selected from groups A′) to C′) as defined in the description, and to compositions comprising these mixtures. | 2012-03-22 |
20120070422 | Method of Treating Ocular Disorders - A method wherein subjects having or at risk for having hyperopia, presbyopia or astigmatism are administered a composition having an effective amount of ocular antioxidants, including specifically macular pigments, to prevent, treat, or delay the onset of age-related macular degeneration (AMD). | 2012-03-22 |
20120070423 | ORAL COMPOSITION AND METHOD OF FORMING AND USING SAME - An oral composition for the treatment of dry mouth symptoms and other conditions, a method of forming the oral composition, and a method of using the oral composition are disclosed. The oral composition includes a plurality of enzymes to prevent formation of and/or facilitate the break up of biofilm in an oral cavity and a metal ion management system to inhibit growth of gram negative bacteria. | 2012-03-22 |
20120070424 | Mutations on OAS1 Genes - Modified amino acid sequences of OAS1 proteins in non-human primates, and genes related thereto, are provided. | 2012-03-22 |
20120070425 | TISSUE KALLIKREIN FOR THE TREATMENT OF PANCREATIC Beta-CELL DYSFUNCTION AND FOR Beta-CELL PROLIFERATION - The invention relates to methods of administering kallikrein, a variant, or active fragment thereof to stimulate proliferation of islet cells generally and β-cells specifically. The invention also includes compositions to stimulate proliferation in vivo and in vitro. | 2012-03-22 |
20120070426 | PEPTIDE-BASED PASSIVE IMMUNIZATION THERAPY FOR THE TREATMENT OF ATHEROSCLEROSIS - The present invention relates to passive immunization for treating or preventing atherosclerosis using an isolated human antibody directed towards at least one oxidized fragment of apolipoprotein B in the manufacture of a pharmaceutical composition for therapeutical or prophylactical treatment of atherosclerosis by means of passive immunization, as well as method for preparing such antibodies, and a method for treating a mammal, preferably a human using such an antibody to provide for passive immunization. | 2012-03-22 |
20120070427 | VORTEX-INDUCED SILK FIBROIN GELATION FOR ENCAPSULATION AND DELIVERY - The present invention provided for a novel process of forming silk fibroin gels, and controlling the rate of β-sheet formation and resulting hydrogelation kinetics, by vortex treatment of silk fibroin solution. In addition, the vortex treatment of the present invention provides a silk fibroin gel that may be reversibly shear-thinned, enabling the use of these approach for precise control of silk self-assembly, both spatially and temporally. Active agents, including biological materials, viable cells or therapeutic agents, can be encapsulated in the hydrogels formed from the processes, and be used as delivery vehicles. Hence, the present invention provide for methods for silk fibroin gelation that are useful for biotechnological applications such as encapsulation and delivery of active agents, cells, and bioactive molecules. | 2012-03-22 |
20120070428 | TREATMENT OF VASCULARIZED PIGMENT EPITHELIAL DETACHMENT WITH ANTI-VEGF THERAPY - Methods for treating vascularized pigment epithelial detachment using anti-VEGF agents are disclosed. | 2012-03-22 |
20120070429 | HUMANIZED ANTIBODIES AGAINST WEST NILE VIRUS AND THERAPEUTIC AND PROPHYLACTIC USES THEREOF - The present invention relates to compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to one or more antigens of a flavivirus, particularly of West Nile Virus (WNV) and methods for preventing, treating or ameliorating symptoms associated with a flavivirus, particularly of West Nile Virus (WNV) infection utilizing said compositions. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with WNV infection, said methods comprising administering to a human subject an effective amount of one or more humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen. The present invention also relates to detectable or diagnostic compositions comprising humanized antibodies or fragments thereof that immunospecifically bind to a WNV antigen and methods for detecting or diagnosing WNV infection utilizing said compositions. | 2012-03-22 |
20120070430 | IDENTIFICATION OF TUMOR-ASSOCIATED MARKERS FOR DIAGNOSIS AND THERAPY - The invention relates to genetic products the expression of which is associated with cancer diseases. The invention also relates to the therapy and diagnosis of diseases in which the genetic products are expressed or aberrantly expressed, in particular cancer diseases. | 2012-03-22 |
20120070431 | METHODS FOR TREATING CHRONIC OBSTRUCTIVE PULMONARY DISEASE - The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status, with a therapeutically effective amount of an anti-IgE moiety. In accordance with the invention, COPD patients with an elevated serum IgE level may benefit from the treatment methods disclosed. In certain instances, the methods of the disclosure have been found to be useful for the treatment of COPD patients regardless of their skin test results and/or in vitro reactivity to a perennial aeroallergen. Anti-IgE moieties, in accordance with the invention, include but are not limited to any IgG antibody that selectively binds to a given mammal immunoglobulin E (e.g., human immunoglobulin E) such as humanized anti-IgE, humanized murine monoclonal antibody, and/or Omalizumab. | 2012-03-22 |
20120070432 | TREATMENT OF PANCREATIC CANCER USING A DR5 AGONIST IN COMBINATION WITH GEMCITABINE - Methods and compositions for treatment of exocrine pancreatic cancer in a human patient comprising administering a therapeutically effective amount of a DR5 agonist and gemcitabine. Methods and compositions for treating a patient by identifying the alleleic variant of FcγRIIIA. | 2012-03-22 |
20120070433 | FLAVONOID HYDROGEL - There is provided methods for producing a hydrogel comprising conjugates of a hydrogel forming agent and a flavonoid including a method for producing a hydrogel that is capable of adhesion of cells and which comprises enzymatically cross-linked conjugates of a hydrogel forming agent and a flavonoid. There is also provided a method for producing a hydrogel comprising conjugates of a hydrogel forming agent and a flavonoid without the addition of an exogenous peroxide or peroxidase or without the addition of an exogenous peroxide. Hydrogels produced by such methods and methods of using the hydrogels are also described herein. | 2012-03-22 |
20120070434 | ANTIBODIES CONTAINING THERAPEUTIC TPO/EPO MIMETIC PEPTIDES - The present disclosure features therapeutic antibodies (e.g., TPO mimetic antibodies) and therapeutically-active fragments thereof as well as methods for preparing and using the antibodies and fragments. For example, the therapeutic antibodies and their fragments are useful in a variety of diagnostic and/or therapeutic applications such as methods for increasing platelet levels in a subject. | 2012-03-22 |
20120070435 | CHIMERIC ANTIGENS FOR ELICITING AN IMMUNE RESPONSE - Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular embodiments, the compounds and methods elicit immune responses against antigens that are otherwise recognized by the host as “self” antigens. The immune response is enhanced by presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises a xenotypic antibody fragment. By virtue of the target binding domain, antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response. | 2012-03-22 |
20120070436 | ANTIGEN-BINDING PROTEINS - The present invention relates to antigen binding proteins comprising a receptor-Fc fusion which is linked to one or more epitope-binding domains, methods for making such proteins, and uses thereof. | 2012-03-22 |
20120070437 | METHOD OF IDENTIFYING COMPOUNDS THAT BIND BAFF-R - Disclosed are nucleic acids encoding BAFF-R polypeptides, as well as antibodies to BAFF-R polypeptides and pharmaceutical compositions including the same. Methods of treating tumorigenic and autoimmune conditions using the nucleic acids, polypeptides, antibodies and pharmaceutical compositions of this invention are also provided. | 2012-03-22 |
20120070438 | Methods for Treating Melanoma - Methods of inhibiting melanoma tumor growth, methods of treating melanoma and metastatic melanoma, and methods of reducing the frequency of tumor initiating cells (or cancer stem cells) in melanoma tumors are described. The methods described comprise administering a DLL4 antagonist (e.g., an antibody that specifically binds the extracellular domain of human DLL4) to a subject. Related polypeptides and polynucleotides, compositions comprising the DLL4 antagonists, and methods of making the DLL4 antagonists are also described. | 2012-03-22 |
20120070439 | ANTIGEN-BINDING PROTEINS - The invention relates to linkers suitable for use in antigen-binding proteins, certain antigen binding proteins and methods of making such proteins and uses thereof. | 2012-03-22 |
20120070440 | THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES - The present invention is directed to antagonists of CS1 that bind to and neutralize at least one biological activity of CS1. The invention also includes a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides for a method of preventing or treating disease states, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering into said subject an effective amount of such antagonists. | 2012-03-22 |
20120070441 | EXTRACELLULAR YALURONIDASE FROM STREPTOMYCES KOGANEIENSIS - The invention relates to | 2012-03-22 |
20120070442 | METHODS AND COMPOSITIONS FOR TREATING CANCER - Provided herein are methods for identifying a cancer patient responsive to treatment with an EGFR tyrosine kinase inhibitor. One method comprises obtaining a biopsy from the patient and measuring the number of copies of miR-128 | 2012-03-22 |
20120070443 | PDE1 AS A TARGET THERAPEUTIC IN HEART DISEASE - Disclosed are compositions and methods related to inhibition of PDE1. | 2012-03-22 |
20120070444 | IN VIVO SCREENING MODELS FOR TREATMENT OF isoQC-RELATED DISORDERS - A transgenic non-human animal for overexpressing isoQC, comprising cells containing a DNA transgene encoding human isoQC, characterized in that said human isoQC comprises the amino acid sequence of SEQ ID NO: 1 or an amino acid sequence having at least 75% sequence identity to the amino acid sequence of SEQ ID NO: 1 or a fragment or derivative of the amino acid sequence of SEQ ID NO: 1. Additionally disclosed is a method of screening for biologically active agents that inhibit or promote isoQC. | 2012-03-22 |
20120070445 | BRAIN-DERIVED GONADOTROPINS AND COGNITION - A method of treating or preventing neurodegenerative disease in a subject, the method includes administering to the subject a therapeutically effective amount of at least one physiologically acceptable agent that modulates levels, production, and/or function of brain-derived hormones of the hypothalamic-pituitary-gonadal (HPG) axis or their receptors. | 2012-03-22 |
20120070446 | RSV SPECIFIC BINDING MOLECULE - The invention provides antibodies and functional equivalents thereof which are capable of specifically binding RSV. Nucleic acid sequences encoding said antibody, as well as antibody producing cells and methods for producing said antibody are also provided. | 2012-03-22 |
20120070447 | METHODS OF ADMINISTERING / DOSING ANTI-RSV ANTIBODIES FOR PROPHYLAXIS AND TREATMENT - The present invention encompasses novel antibodies and fragments thereof which immunospecifically bind to one or more RSV antigens and compositions comprising said antibodies and antibody fragments. The present invention encompasses methods preventing respiratory syncytial virus (RSV) infection in a human, comprising administering to said human a prophylactically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention also encompasses methods for treating or ameliorating symptoms associated with a RSV infection in a human, comprising administering to said human a therapeutically effective amount of one or more antibodies or fragments thereof that immunospecifically bind to one or more RSV antigens, wherein a certain serum titer of said antibodies or antibody fragments is achieved in said human subject. The present invention further encompasses compositions comprising antibodies or fragments thereof that immunospecifically bind to a RSV antigen, and methods using said compositions for detection or diagnosis a RSV infection | 2012-03-22 |
20120070448 | ANTI-IL-3RA ANTIBODY FOR USE IN TREATMENT OF BLOOD TUMOR - The present invention provides an antibody to human IL-3Rα chain, which does not inhibit IL-3 signaling and binds to B domain of the human IL-3Rα chain but does not bind to C domain of the human IL-3Rα chain; a composition for preventing or treating a blood tumor in which a cell expressing IL-3Rα is found in bone marrow or peripheral blood of a subject, which comprises the antibody to human IL-3Rα as an active ingredient; and a method for treating a blood tumor in which a cell expressing IL-3Rα is found in bone marrow or peripheral blood, which comprises administering, to a subject, a composition comprising the IL-3Rα antibody as an active ingredient. | 2012-03-22 |
20120070449 | METHODS OF TREATING INFLAMMATION - A method of treating an inflammation in a subject in need thereof is disclosed. The method comprising administering to the subject an agent capable of down-regulating an activity or expression of CD151 in a lymphocyte, with the proviso that the agent is not CCL2, thereby treating the inflammation. | 2012-03-22 |
20120070450 | LEUKEMIA STEM CELL MARKERS - The invention provides a test method for predicting the initial onset or a recurrence of acute myeloid leukemia (AML) comprising (1) measuring the expression level of human leukemic stem cell (LSC) marker genes in a biological sample collected from a subject for a transcription product or translation product of the gene as an analyte and (2) comparing the expression level with a reference value; an LSC-targeting therapeutic agent for AML capable of suppressing the expression of a gene selected from among LSC marker genes or a substance capable of suppressing the activity of a translation product of the gene; a method for producing a sample containing hematopoietic cells for autologous transplantation or allogeneic transplantation for AML patients comprising obtaining an LSC-purged sample with at least 1 kind of LSC marker as an index; and a method of preventing or treating AML. | 2012-03-22 |
20120070451 | METHODS AND COMPOSITIONS FOR MODULATING CARDIAC CONTRACTILITY - Provide is a Ca | 2012-03-22 |
20120070452 | IMMUNOADJUVANT COMPOSITION AND USE THEREOF - Disclosed is a composition comprising, as an active ingredient, at least one selected from the group consisting of a Zc3h12a gene inhibitor and a Zc3h12a protein inhibitor. This composition can be used as an immunoadjuvant. | 2012-03-22 |
20120070453 | Methods for Preparing and Delivering Adjuvant Compositions - Methods are provided for preparing and delivering an adjuvant for vaccines including lecithin and a polymer. The polymer is preferably polyacrylic acid-based and the delivery method involves administering a vaccine, including an antigen and the adjuvant, to a mucosal surface. | 2012-03-22 |
20120070454 | DENGUE VACCINE, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, NUCLEOTIDE SEQUENCE AND ANTIBODY COMPOSITION - The present invention relates to a dengue vaccine, a pharmaceutical composition comprising the same, a nucleotide sequence, and an antibody composition. The dengue vaccine of the present invention includes chimeric nonstructural protein 1, which comprises N-terminus of DV NS1 from amino-acid residues 1 to 270 and C-terminus of JEV NS1 from amino-acid residues 271 to 352 (designated DJ NS1). Therefore, the dengue vaccine without autoimmunity according to the present invention is able to avoid cross-reactions with endothelial cells and platelets, and is able to shorten the bleeding time. | 2012-03-22 |
20120070455 | INFLUENZA VACCINE - The present invention discloses isolated peptides encoding an antigen or fragments thereof from the N-terminus of hemagglutinin protein of influenza, methods for isolating such antigens and specific uses thereof. The peptide can be used as a vaccine to generate an antibody response that neutralizes influenza infectivtty against a variety of influenza strains. | 2012-03-22 |
20120070456 | POLYPEPTIDE CARRIER PROTEIN - The invention relates to polypeptide carrier proteins that comprise at least five CD4+ T cell epitopes, for conjugation to capsular polysaccharides. The carrier proteins are useful as components of vaccines that can elicit a T-cell dependent immune response. These vaccines are particularly useful to confer protection against infection from encapsulated bacteria in infants between the ages of 3 months and about 2 years. | 2012-03-22 |
20120070457 | Polypeptides from neisseria meningitidis - Polypeptides comprising | 2012-03-22 |
20120070458 | ADJUVANTING MENINGOCOCCAL FACTOR H BINDING PROTEIN - Factor H binding protein (fHBP) has been proposed for use in immunising against serogroup B meningococcus (‘MenB’). This antigen can be efficiently adsorbed to an aluminium hydroxyphosphate adjuvant by (i) ensuring that adsorption takes place at a pH which is equal to or below the adjuvant's point of zero charge (PZC), and/or (ii) selecting a fHBP and adjuvant with an isoelectric point/PZC within the range of 5.0 to 7, and/or (iii) selecting a fHBP with an isoelectric point above the adjuvant's PZC and using a buffer to bring the pH to within 1.2 pH units of the PZC. The adsorption is particularly useful for compositions which include multiple fHBP variants, and also in situations where an aluminium hydroxide adjuvant should be avoided. Buffered pharmaceutical compositions can include at least two different meningococcal fHBP antigens, both of which are at least 85% adsorbed to aluminium hydroxyphosphate adjuvant. | 2012-03-22 |
20120070459 | METHOD FOR KEEPING A FOOT-AND-MOUTH DISEASE VACCINE AVAILABLE FOR EMERGENCY VACCINATION - The present invention pertains to a method for keeping a foot-and-mouth disease vaccine available for emergency vaccination of animals against foot-and-mouth disease, the vaccine comprising a foot-and-mouth disease antigen formulated in a water-in-oil emulsion, the method comprising the steps of providing the formulated vaccine, freezing the vaccine, and storing the frozen vaccine until it is needed for emergency vaccination. | 2012-03-22 |
20120070460 | DENDRITIC CELL MODULATORY MOLECULE - The present invention provides a dendritic cell modulatory molecule which modulates, and preferable inhibits, the differentiation and maturation of mammalian dendritic cells. The invention also provides pharmaceutical compositions comprising the dendritic cell modulatory molecule and homologues and active fragments thereof, antibodies thereto and methods of treatment and screening methods which utilise such molecules. | 2012-03-22 |
20120070461 | USE OF MYELOID CELL BIOMARKERS FOR THE DIAGNOSIS OF CANCER - The present invention relates to the use of myeloid cell biomarkers for the differential diagnosis, prognosis, and monitoring of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to monitoring the effect of a treatment against renal cell carcinoma (RCC) or colorectal cancer (CRC), and establishing a prognosis of the outcome of the treatment of renal cell carcinoma (RCC) or colorectal cancer (CRC). The present invention furthermore relates to panels of cellular biomarkers for use in the above methods, in particular multicolor panels for measuring said biomarkers. | 2012-03-22 |
20120070462 | Targeted Gene Delivery to Dendritic Cells - Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers. | 2012-03-22 |
20120070463 | METHOD OF BIOTECHNOLOGICAL PRODUCTION FO BOVINE HEMODERIVATIVE AND USE OF BOVINE HEMODERIVATIVE - The method of biotechnological production of bovine hemoderivative is presented in the following overview providing a summary of individual technological operations in time sequence (Flow-Sheet). | 2012-03-22 |
20120070464 | MONOPARAMUNITY INDUCERS BASED ON ATTENUATED RABBIT MYXOMAVIRUSES - The present invention relates to monoparamunity inducers based on paramunizing viruses or viral components of a myxomavirus strain from rabbits with typically generalizing disease, to a method for the production thereof and to the use thereof as medicaments for the regulatory optimization of the paramunizing activities for the prophylaxis and therapy of various dysfunctions in humans and animals. | 2012-03-22 |
20120070465 | PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE - A pharmaceutical composition for modified release comprising (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a maximum blood drug concentration (Cmax) when administered in a fasted state is 400 ng/mL or less, is disclosed. | 2012-03-22 |
20120070466 | Conjugated Polymeric Material and Uses Thereof - Disclosed are compositions comprising collagen covalently bound to particles, wherein covalent bonds are formed between reactive groups of the collagen and reactive groups of the particles, and wherein the particles have an average particle diameter ranging from 20 to 1000 nanometers. Also disclosed are various methods that utilize the compositions. | 2012-03-22 |
20120070467 | Ophthalmic Drug Delivery - The present invention includes and provides a method of delivering a medicament to an eye of a subject in need thereof a solution, the method comprising: (a) providing droplets containing the medicament with a specified average size and average initial ejecting velocity; and (b) delivering the medicament to the eye, where the droplets deliver a percentage of the ejected mass of the droplets to the eye. | 2012-03-22 |
20120070468 | REMOVAL OF TOXINS FROM GASTROINTESTINAL FLUIDS - A process for the removal of toxic cations and anions from gastrointestinal fluids is disclosed. A pH-increasing medication is administered prior to or together with a microporous cation exchanger. An additional feature of the invention is the use of a proton form of the microporous cation exchanger. The acidity of the gastrointestinal fluids is decreased to improve the stability of the microporous cation exchangers, which are represented by the empirical formula: | 2012-03-22 |
20120070469 | BETA-CASEIN ASSEMBLIES FOR MUCOSAL DELIVERY OF THERAPEUTIC BIOACTIVE AGENTS - Nanoparticulate assemblies of isolated β-casein are useful for encapsulation of bioactive therapeutic substances, particularly therapeutic agents with poor bioavailability. The nanoparticulate assemblies can be freeze-dried and re-suspended prior to administration. | 2012-03-22 |
20120070470 | HEMOSTATIC COMPOSITIONS, DEVICES, AND METHODS - Compositions that include a clay such as kaolin dispersed in a liquid such as water may be useful for promoting the clotting of blood. The compositions may be in a liquid, gel, paste, foam, or another form. Uses may include treating a traumatic injury such as in injury caused by a bullet, an explosive, a blade etc., or an injury caused during a medical procedure such as surgery. | 2012-03-22 |
20120070471 | ADMINISTRATION OF ENOXOPARIN SODIUM TO PATIENTS 75 YEARS AND OLDER WITH ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION - Methods for treating ST-segment elevation myocardial infarction in a human patient 75 years of age or older. The methods comprise administering a dose of less than 1 mg per kg body weight, about 0.75 mg per kg of body weight, or 0.75 mg per kg of body weight of enoxaparin sodium by subcutaneous injection approximately every twelve hours for a therapeutic dosing period. The methods may include fibrinolytic therapy. The treatment methods may be used to prevent one or more of, mortality, myocardial re-infarction, myocardial ischemia, stroke, or severe congestive heart failure. Articles of manufacture for use in connection with treating ST-segment elevation myocardial infarction in a human patient 75 years of age or older are also disclosed. | 2012-03-22 |
20120070472 | CHRONOTHERAPEUTIC COMPOSITIONS AND METHODS OF THEIR USE - Chronotherapeutic formulations of cardiovascular drugs are disclosed. The formulations comprise at least one cardiovascular drug that exhibits an in vivo elimination half-life of less than about 8 hours; wherein the formulation exhibits the following in vivo profile following administration to a subject:
| 2012-03-22 |
20120070473 | Apparatus and Method for Reducing the Occurrence of Post-Surgical Adhesions - A method for inhibiting formation of adhesions following abdominal surgery which involves application of an anti-static fatty acid ethoxylated amide (Cocamide DEA) in a matrix that is placed in the peritoneal cavity at the conclusion of an abdominal surgery and which releases this anti-adhesive chemical over a predetermined time in a range up to seven days. Tests conducted on laboratory rats established that the method reduced the incidence of adhesions from 100 percent (100%) in a test model to near zero in the majority of treated animals. In an alternative embodiment, andrographalide was delivered via a pump with similar results. In still another embodiment, an effective amount of 50% phosphatidylchorene and propylene glycol was delivered, via a pump, into the abdominal cavity, again with similar results. | 2012-03-22 |
20120070474 | POLYMER COMPOUND FOR BIOMEDICAL USE AND BIOCHIP SUBSTRATE USING SUCH A POLYMER COMPOUND - A biochip substrate capable of realizing the high detection accuracy by restricting a nonspecific adsorption or bonding of a substance to be detected, when used for a detection or analysis of protein, nucleic acids and the like. The biochip substrate is for fixing a biologically active substance on a surface of a solid substrate, and characterized in that it has a layer comprising a polymer compound obtained by copolymerizing an ethylenically unsaturated polymerizable monomer having an alkylene glycol residue, an ethylenically unsaturated polymerizable monomer having a functional group for fixing a biologically active substance and an ethylenically unsaturated polymerizable monomer having a cross-linkable functional group, on the surface of the substrate. | 2012-03-22 |
20120070475 | Zero Calorie Polyphenol Aqueous Dispersions - A method for stably dispersing microparticulated water insoluble bioactive polyphenol in a beverage by combining the bioactive polyphenol dissolved in an alkaline solution with an aqueous solution of at least one dispersion stabilizer. A composition comprising dispersed microparticulated water insoluble bioactive polyphenol(s) and a dispersion stabilizer. | 2012-03-22 |
20120070476 | Compositions and Methods for Inactivation of Pathogens at Genital Tract Surfaces - The present disclosure includes compositions and methods of inactivating pathogens of a genital tract of a female. The compositions include L-lactic acid substantially free of D-lactic acid. In particular, an intravaginal ring for sustained release of L-lactic acid out of a reservoir containing multi-gram quantities of L-lactic acid, with minimal osmotically induced swelling or pressurization of the reservoir during prolonged use is provided. | 2012-03-22 |
20120070477 | DRY POWDER FIBRIN SEALANT - A fibrin sealant comprises a mixture of first microparticles that comprise fibrinogen, second microparticles that comprise thrombin, and additive material. The additive material may be particulate, and may be, for instance, a biocompatible, water-absorbent, material, a biocompatible, water-swellable material, a biocompatible, water-insoluble material, a polysaccharide or silica. | 2012-03-22 |
20120070478 | COLOR CHANGING CONSUMER PRODUCTS - The invention relates to personal care products containing multilayer films with decorative layers and may impart a noticeable color change. The invention is applicable in products including type toothpaste, soaps, and other products until diluted with water (or saliva). | 2012-03-22 |
20120070479 | SALINE NOSE WIPE AND METHODS OF MANUFACTURE AND USE - The present invention generally relates to a wet wipe or sheet that is suitable for contacting the skin and removing mucus from the skin. More specifically, the present invention relates to a wet wipe having an aqueous saline component suitable for dissolving and removing mucus in combination with the fabric matrix of the wet wipe. Typically, the fabric matrix of the wet wipe has a capacity of about 125 grams of solution per square meter, and it is impregnated with the aqueous saline solution to a level at or below approximately 80% of the absorbent capacity of the matrix. | 2012-03-22 |
20120070480 | ANTIMICROBIAL DISPOSABLE ABSORBENT ARTICLES - Disposable absorbent articles comprising an absorbent material and an antimicrobial composition are disclosed. The antimicrobial composition includes a carrier comprising fatty alcohol and a poly(alkyleneoxy) polymer, and an antimicrobial agent. The antimicrobial composition may be coated on to component substrates such as nonwovens and films, that are incorporated into disposable absorbent articles, such as disposable infant diapers, adult incontinence articles, feminine hygiene articles such as sanitary napkins, wound dressings, bandages, panty liners and tampons, personal care wipes and household wipes to provide odor control, and control of microbial growth. | 2012-03-22 |
20120070481 | STABLE AQUEOUS SOLUTIONS OF SILANE QUAT AMMONIUM COMPOUNDS - Textiles coated with aqueous compositions of silane quaternary ammonium compounds and alkali metal bicarbonates are provided with deodorization properties and protection from allergens, irritants, molds, dust mites, bacteria, and fungi. | 2012-03-22 |
20120070482 | FORMULATION COMPRISING AVERMECTIN PARTICLES COATED WITH A PHOTO-PROTECTING AGENT - A composition comprising a pesticide (A) selected from avermectin and a photo-protecting agent, wherein the mean diameter of the pesticide (A) particles is from 0.1 to 100 μm and where the amount of photo-protecting agent in the composition does not exceed 20% of the total weight of the pesticide (A) particles plus the agent, and its use in agriculture. The avermectin particles are preferably coated with the photo-protecting agent. | 2012-03-22 |
20120070483 | Multi-Functional Biocompatible Coatings for Intravascular Devices - A polymeric coating is adapted to substantially eliminate thrombus formation when in contact with blood. The polymeric coating includes a first polymeric layer and a second polymeric layer. Interposed between the first and second polymeric layers is a polymeric matrix layer doped with at least one of a nitric oxide donor and a nitric oxide generator. The nitric oxide donor and/or the nitric oxide generator are capable of releasing or generating NO. A bioactive agent is either immobilized to the surface of the second polymeric layer or is incorporated into the polymeric matrix layer. | 2012-03-22 |
20120070484 | WATER-ABSORBING RESIN COMPOSITION - A water-absorbent resin composition having an antimicrobial property, which suppresses the generation of dust of the antimicrobial agent. A water-absorbent resin composition comprising a water-absorbent resin and an antimicrobial agent comprising an inorganic compound carrying an antimicrobial metal, the water-absorbent resin composition being characterized in that the degree of generated dust of the water-absorbent resin composition is at most 100 CPM. The water-absorbent resin composition of the present invention can be suitably used as hygienic materials such as disposable diaper, sanitary napkin and incontinence pad; urine-absorbent materials for pets; materials for civil engineering and construction such as packing materials; drip absorbents; food freshness retaining materials such as cold-reserving agents; horticultural articles such as water-retaining materials for soils; and the like. | 2012-03-22 |
20120070485 | METHOD FOR PRODUCING A DEVICE APPLICABLE TO BIOLOGICAL TISSUES, PARTICULARLY A PATCH FOR TREATING DAMAGED TISSUES, AND A DEVICE OBTAINED BY SAID METHOD - The present invention relates to a device consisting of cross-linked nanofibrillary fibrin supported on and rooted to a microporous nonwoven fabric consisting of a biocompatible synthetic polymer material. An active ingredient is advantageously dispersed in the fibrin layer. The fibrin layer does not have a haemostatic function, but is suitable for retaining the active ingredient and releasing it with controlled kinetics. The device forming the object of the invention, preferably in the form of patches, is useful for in vitro cell cultures or for treating tissues damaged by wounds or necrosis, such as cardiac walls bearing the sequelae of infarction, or a tissue damaged by a diabetic ulcer. The patch according to the invention can be manufactured by inducing the polymerisation of the fibrin, under suitable conditions, directly on the support layer, which is suitably impregnated with thrombin (at least in a superficial portion of its thickness), and which has been conveniently prepared by means of a spray phase-inversion technique. | 2012-03-22 |
20120070486 | METHODS AND COMPOSITIONS RELATED TO PREFOLDIN AND ITS REGULATION - The present invention relates to the fields of molecular biology and drug delivery. In certain embodiments, the present invention provides methods for the delivery of a siNA (e.g., a siRNA) to a cell to modulate expression of a PFDN 1-6. These methods may be used to treat a disease, such as cancer. | 2012-03-22 |
20120070487 | ALKYLSACCHARIDE COMPOSITIONS WITH NUTRACEUTICALS - The present invention provides nutraceutical compositions with enhanced oral bioavailability. The compositions of the present invention include one or more alkylsaccharides admixed with one or more nutraceutical. | 2012-03-22 |
20120070488 | METHOD OF INDUCING NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS - The present invention relates, in general, to human immunodeficiency virus (HIV), and, in particular, to a method of inducing neutralizing antibodies to HIV and to compounds and compositions suitable for use in such a method. | 2012-03-22 |
20120070489 | COMBINATION THERAPY FOR TREATMENT OF FIV INFECTION - The present invention pertains to methods for therapeutic and prophylactic treatment of cats against FIV infection. Methods of the present invention utilize a combination of antiretroviral compounds to treat or prevent FIV infection in a feline animal. In one embodiment, the method comprises administering an effective amount of AZT and another nucleoside analog, such as, for example, 3TC to the animal. In another embodiment, cats are given an effective dose(s) of AZT, 3TC, and a retroviral protease inhibitor. | 2012-03-22 |
20120070490 | ANTI-TRYPANOSOMAL PEPTIDES AND USES THEREOF - The present invention provides methods of killing, inhibiting the growth, and/or inhibiting the reproduction of kinetoplastid protozoan with hydrophobic signal sequence peptides and compositions including such hydrophobic signal sequence peptides. | 2012-03-22 |
20120070491 | CASB7439 CONSTRUCTS - The present disclosure relates to compounds and methods for increasing the recombinant production of CASB7439 polypeptides, and for methods of utilizing the same. | 2012-03-22 |
20120070492 | RHEIN OR DIACEREIN COMPOSITIONS - The invention relates to pharmaceutical compositions comprising rhein or diacerein or salts or esters or prodrugs thereof, optionally with one or more pharmaceutically acceptable excipients. The invention also relates to the methods for preparing such compositions. | 2012-03-22 |
20120070493 | TARGETED MULTI-EPITOPE DOSAGE FORMS FOR INDUCTION OF AN IMMUNE RESPONSE TO ANTIGENS - Provided herein are compositions and methods related to MHC II binding peptides. In some embodiments, the peptides are obtained or derived from a common source. In other embodiment, the peptides are obtained or derived from an infectious agent to which a subject has been repeatedly exposed. | 2012-03-22 |
20120070494 | Treatment for Attention-Deficit Hyperactivity Disorder - A method for treating Attention Deficit/Hyperactivity Disorder (ADHD) in humans and the symptoms associated therewith, inattentiveness, and hyperactivity with impulsivity, using eltoprazine and related compounds is provided. | 2012-03-22 |
20120070495 | ORAL FORMULATIONS AND LIPOPHILIC SALTS OF METHYLNALTREXONE - The present invention provides compositions comprising methylnaltrexone or a salt thereof, and compositions and formulations thereof, for oral administration. | 2012-03-22 |
20120070496 | ANTIDEPRESSANT DOSAGE FORM - A dosage form having sustained-release or controlled-release properties for delivering 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]-cyclohexanol from the dosage form over an extended period of time in a therapeutically responsive dose to produce antidepressant therapy. | 2012-03-22 |
20120070497 | USE OF BOSWELLIC ACIDS FOR THE PROPHYLAXIS AND/OR TREATMENT OF DAMAGE TO AND/OR INFLAMMATION OF THE ISLETS OF LANGERHANS - Disclosed are methods and compositions related to the use of boswellic acids (such as acetyl-11-keto-β-boswellic acid, 11-keto-β-boswellic acid, β-boswellic acid, acetyl-β-boswellic acid, 9,11-dehydro-β-boswellic acid, acetyl-9,11-dehydro-β-boswellic acid, α-boswellic acid, acetyl-α-boswellic acid, 11-dehydro-α-boswellic acid, acetyl-9,11-dehydro-α-boswellic acid, lupeolic acid, acetyl lupeolic acid, 12-ursene-2-diketone, incensole, incensole acetate, a derivative, in particular an ester thereof, a pharmaceutically acceptable salt thereof, a combination thereof, or a preparation containing one or more of these compounds) for the human medical or veterinary prophylaxis and/or treatment of: a) damage to and/or inflammation of the islets of Langerhans and/or b) damage to the B-cells of the islets of Langerhans. | 2012-03-22 |
20120070498 | Submicron Particles of Antineoplastic Agents - The present invention is concerned with the formation of submicron particles of an antineoplastic agent, particularly paclitaxel, by precipitating the antineoplastic agent in an aqueous medium to form a pre-suspension followed by homogenization. Surfactants with phospholipids conjugated with a water soluble or hydrophilic polymer such as PEG are used as coating for the particles. The particles produced generally have an average particle size of less than about 1000 nm and are not rapidly soluble. | 2012-03-22 |
20120070499 | DELAYED-RELEASE GLUCOCORTICOID TREATMENT OF RHEUMATOID DISEASE - The present invention refers to the treatment of a rheumatic disease and/or osteoarthritis by administering a delayed-release dosage form of a glucocorticoid to a subject in need thereof. | 2012-03-22 |
20120070500 | Nanoparticles Of Cerium Oxide Targeted To An Amyloid-Beta Antigen Of Alzheimer's Disease And Associated Methods - Disclosed is a composition immunologically targeted to Alzheimer's disease (AD), the composition containing amine functionalized nanoparticles of Cerium oxide coated with polyethylene glycol and bearing an antibody specific for an amyloid-beta antigen associated with AD. The invention also includes a medication manufactured with the targeted nanoceria particles and methods of treatment by administering the targeted nanoceria particles to patients in need thereof. | 2012-03-22 |
20120070501 | Method and Formulation for Treating Resistance to Antihypertensives and Related Conditions - A method for the prevention or treatment of symptoms of hypertension in a patient who is resistant to antihypertensive effects of an antihypertensive compound administered in the absence of melatonin comprises administering to said patient melatonin in an amount effective to ameliorate or prevent symptoms of hypertension in said patient. | 2012-03-22 |
20120070502 | METHODS OF TREATING CANCER - The present invention provides methods and compositions for treating non-small-cell lung cancer (NSCLC) by administering a) a composition comprising nanoparticles that comprise paclitaxel and an albumin and b) a platinum-based agent (e.g., carboplatin). The present application also provides methods of treating prostate cancer by administering to the individual a) an effective amount of a composition comprising nanoparticles comprising docetaxel and an albumin; and b) an effective amount of a steroid. | 2012-03-22 |
20120070503 | Nanoparticle-Based Targeted Drug Delivery For In Vivo Bone Loss Mitigation - The present invention is directed to nanoparticle-based targeted drug delivery system for treatment of bone-loss. An enantiomeric phenothiazine is formulated into an in-vivo nanoparticle delivery system which may contain bone-targeting functionality. The nanoparticle formulations and their associated influence on whole bone porosity may now also be evaluated utilizing nuclear magnetic resonance (NMR) and relaxation time profiles, and in particular, median T | 2012-03-22 |
20120070504 | PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF THE SYMPTOMS OF ADDICTION AND METHOD OF DIAGNOSING SAME - A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed. | 2012-03-22 |
20120070505 | FUNCTIONAL AMPHIPILIC MOLECULE OR MACROMOLECULE FORMULATIONS WITH MULTIPLE COMPARTMENTS - The invention relates to novel functional amphiphilic molecule or macromolecule formulations with multiple compartments for transporting or targeting at least one therapeutic agent, in particular an antitumor agent, as well as to a method for preparing such formulations and to the use thereof. | 2012-03-22 |
20120070506 | Animal Treatment - The present invention relates to a composition for an animal within a particular weight range including at least one non-steroidal anti-inflammatory drug (NSAID) compound and at least one mussel extract characterised in that the therapeutic dose of NSAID compound in the composition is substantially less than the usual therapeutic dose. | 2012-03-22 |
20120070507 | Compositions and Methods for the Treatment of Soft Tissue Injury - Provided herein are compositions and methods for the treatment of soft tissue injury, sports-related injury, physical overuse of muscles, ligaments or joints, and trauma, traumatic stress or sudden jolts on bones and tissues in an individual. Described herein are pharmaceutical compositions comprising a vasoconstrictor and, optionally, a topical analgesic and methods of using said compositions for the treatment of a variety of soft tissue injuries. | 2012-03-22 |
20120070508 | Methods, Compositions, and Devices for Managing Chlorine Dioxide Release - Certain exemplary embodiments can provide a system, machine, device, manufacture, circuit, composition of matter, and/or user interface adapted for and/or resulting from, and/or a method and/or machine-readable medium comprising machine-implementable instructions for, activities that can comprise and/or relate to, a composition comprising molecular matrix-residing chlorine dioxide and/or one or more hygroscopic and/or deliquescent salts. | 2012-03-22 |
20120070509 | SILVER-BASED INORGANIC ANTIMICROBIAL AGENT, METHOD FOR PREPARING THE SAME AND ANTIMICROBIAL PRODUCT - Disclosed is a silver-based inorganic antimicrobial agent which exhibits superior heat resistance, chemical resistance, processability and long-lasting waterproofness. | 2012-03-22 |
20120070510 | WOUND AND MUCOUS MEMBRANE DISINFECTANT - Aqueous wound and mucous membrane disinfectant containing a) octenidine dihydrochloride, and b) one or more active ingredients selected from the group ethanol, 1-propanol, 2-propanol, undecylene amidopropyl trimonium methosulfate, 3-(4-chlorophenoxy)-1,2-propanediol and/or sodium hydroxymethylglycinate and c) glycerin and/or 1,2-diols having 3 to 10 carbon atoms, and d) optionally surfactants, emulsifiers, solubilisers, pH regulators, dyestuffs, perfumes and/or thickeners, the agent being free of phenoxyethanol, phenoxypropanol, phenoxyisopropanol and organic acids. | 2012-03-22 |
20120070511 | MITOCHONDRIAL INHIBITORS AND USES THEREOF - Compositions which modulate mitochondrial functions treat diseases associated with cells that are hyperactively using their endoplasmic reticulum. Screening assays identify agents which modulate mitochondrial functions. | 2012-03-22 |